OncoMatch/Clinical Trials/NCT05288205
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Is NCT05288205 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including JAB-21822 and JAB-3312 for kras p.g12c.
Treatment: JAB-21822 · JAB-3312 — This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Biomarker criteria
Required: KRAS p.G12C mutation
harboring KRAS p.G12C mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
The organ functions of subjects meet the criteria for the following laboratory parameters at screening
Kidney function
The organ functions of subjects meet the criteria for the following laboratory parameters at screening
Liver function
The organ functions of subjects meet the criteria for the following laboratory parameters at screening
Cardiac function
Subjects who have impaired cardiac functions or clinically significant cardiac diseases
The organ functions of subjects meet the criteria for the following laboratory parameters at screening; Subjects who have impaired cardiac functions or clinically significant cardiac diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify